Clinical Trial Update: PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on whether darbepoetin alfa can prevent progression to end-stage kidney disease in chronic kidney disease patients with non-diabetic kidney…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetes Mellitus

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Conditions: Chronic Kidney Disease, Diabetes | Phase 3 | Status: COMPLETED